Amifampridine (phosphate)

Amifampridine (3,4-Diaminopyridine) phosphate is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB) . Amifampridine phosphate is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine phosphate increases transmitter release from neuromuscular junctions (NMJs) . Amifampridine phosphate can be used for Lambert-Eaton myasthenic syndrome (LEMS) research[1][2][3].

Product Specifications

CAS Number

[446254-47-3]

Product Name Alternative

3,4-Diaminopyridine (phosphate)

UNSPSC

12352005

Hazard Statement

H300-H311-H315-H319-H330-H335

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/amifampridine-phosphate.html

Solubility

10 mM in DMSO

Smiles

NC1=C(N)C=CN=C1.O=P(O)(O)O

Molecular Formula

C5H10N3O4P

Molecular Weight

207.12

Precautions

P260-P261-P264-P270-P271-P280-P284-P302+P352-P304+P340-P305+P351+P338-P330-P361+P364-P362+P364-P403+P233-P405-P501

References & Citations

[1]Maarten J Titulaer, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10 (12) :1098-107.|[2]T L Harris, et al. Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. Chem Commun (Camb) . 2016 Mar 18;52 (22) :4187-90.|[3]Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021 Jan-Jun;296:100302.